Selected research
Industry Research
Prophylactic HIV Drug Industry Research Report 2026
Market perspective
The global Prophylactic HIV Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Prophylactic HIV Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Prophylactic HIV Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Prophylactic HIV Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Prophylactic HIV Drug include Merck, Mylan, Roche, Gilead Sciences, Cipla and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Prophylactic HIV Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Prophylactic HIV Drug Market by Company
Merck
Mylan
Roche
Gilead Sciences
Cipla
Bristol-Myers Squibb
Prophylactic HIV Drug Segment by Type
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Integrase Inhibitor
Prophylactic HIV Drug Segment by Application
Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Prophylactic HIV Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prophylactic HIV Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prophylactic HIV Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prophylactic HIV Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Prophylactic HIV Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Prophylactic HIV Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Prophylactic HIV Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
- Integrase Inhibitor
Applications
- Retail Pharmacy
- Online Pharmacy
- Hospital Pharmacy
Companies covered
- Merck
- Mylan
- Roche
- Gilead Sciences
- Cipla
- Bristol-Myers Squibb
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Prophylactic HIV Drug Market Size (2021-2032)
- 2.2.2 Global Prophylactic HIV Drug Sales (2021-2032)
- 2.2.3 Global Prophylactic HIV Drug Market Average Price (2021-2032)
- 2.3 Prophylactic HIV Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
- 2.3.3 Integrase Inhibitor
- 2.4 Prophylactic HIV Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacy
- 2.4.3 Online Pharmacy
- 2.4.4 Hospital Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Prophylactic HIV Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Prophylactic HIV Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Prophylactic HIV Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Prophylactic HIV Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Prophylactic HIV Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Prophylactic HIV Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Prophylactic HIV Drug, Product Type & Application
- 3.8 Global Manufacturers of Prophylactic HIV Drug, Established Date
- 3.9 Global Prophylactic HIV Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Prophylactic HIV Drug Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 Mylan
- 4.2.1 Mylan Company Information
- 4.2.2 Mylan Business Overview
- 4.2.3 Mylan Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Prophylactic HIV Drug Product Portfolio
- 4.2.5 Mylan Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roche Prophylactic HIV Drug Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Gilead Sciences
- 4.4.1 Gilead Sciences Company Information
- 4.4.2 Gilead Sciences Business Overview
- 4.4.3 Gilead Sciences Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gilead Sciences Prophylactic HIV Drug Product Portfolio
- 4.4.5 Gilead Sciences Recent Developments
- 4.5 Cipla
- 4.5.1 Cipla Company Information
- 4.5.2 Cipla Business Overview
- 4.5.3 Cipla Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Cipla Prophylactic HIV Drug Product Portfolio
- 4.5.5 Cipla Recent Developments
- 4.6 Bristol-Myers Squibb
- 4.6.1 Bristol-Myers Squibb Company Information
- 4.6.2 Bristol-Myers Squibb Business Overview
- 4.6.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bristol-Myers Squibb Prophylactic HIV Drug Product Portfolio
- 4.6.5 Bristol-Myers Squibb Recent Developments
5 Global Prophylactic HIV Drug Market Scenario by Region
- 5.1 Global Prophylactic HIV Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Prophylactic HIV Drug Sales by Region: 2021-2032
- 5.2.1 Global Prophylactic HIV Drug Sales by Region: 2021-2026
- 5.2.2 Global Prophylactic HIV Drug Sales by Region: 2027-2032
- 5.3 Global Prophylactic HIV Drug Revenue by Region: 2021-2032
- 5.3.1 Global Prophylactic HIV Drug Revenue by Region: 2021-2026
- 5.3.2 Global Prophylactic HIV Drug Revenue by Region: 2027-2032
- 5.4 North America Prophylactic HIV Drug Market Facts & Figures by Country
- 5.4.1 North America Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Prophylactic HIV Drug Sales by Country (2021-2032)
- 5.4.3 North America Prophylactic HIV Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Prophylactic HIV Drug Market Facts & Figures by Country
- 5.5.1 Europe Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Prophylactic HIV Drug Sales by Country (2021-2032)
- 5.5.3 Europe Prophylactic HIV Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Prophylactic HIV Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Prophylactic HIV Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Prophylactic HIV Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Prophylactic HIV Drug Market Facts & Figures by Country
- 5.7.1 South America Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Prophylactic HIV Drug Sales by Country (2021-2032)
- 5.7.3 South America Prophylactic HIV Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Prophylactic HIV Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Prophylactic HIV Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Prophylactic HIV Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Prophylactic HIV Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Prophylactic HIV Drug Sales by Type (2021-2032)
- 6.1.1 Global Prophylactic HIV Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Prophylactic HIV Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Prophylactic HIV Drug Revenue by Type (2021-2032)
- 6.2.1 Global Prophylactic HIV Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Prophylactic HIV Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Prophylactic HIV Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Prophylactic HIV Drug Sales by Application (2021-2032)
- 7.1.1 Global Prophylactic HIV Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Prophylactic HIV Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Prophylactic HIV Drug Revenue by Application (2021-2032)
- 7.2.1 Global Prophylactic HIV Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Prophylactic HIV Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Prophylactic HIV Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Prophylactic HIV Drug Value Chain Analysis
- 8.1.1 Prophylactic HIV Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Prophylactic HIV Drug Production Mode & Process
- 8.2 Prophylactic HIV Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Prophylactic HIV Drug Distributors
- 8.2.3 Prophylactic HIV Drug Customers
9 Global Prophylactic HIV Drug Analyzing Market Dynamics
- 9.1 Prophylactic HIV Drug Industry Trends
- 9.2 Prophylactic HIV Drug Industry Drivers
- 9.3 Prophylactic HIV Drug Industry Opportunities and Challenges
- 9.4 Prophylactic HIV Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst